Thomson finalizes Solucient purchase

Share this article:
Thomson is buying the balance of Solucient from media giant VNU, private equity firm Veronis Suhler Stevenson and healthcare provider alliance VHA.

Thomson snapped up part of the informatics business—that focused on provision of services to payors—last February.

Now the Stamford-based firm has completed its acquisition of Solucient by picking up its analytics business directed at providers. Those businesses will be folded into Thomson's Medstat informatics unit.

Headquartered in Evanston, IL, Solucient boasts a staff of 500 and a secondary office in Ann Arbor, MI, where Medstat is based. Carol Diephuis, EVP at Thomson Medstat, said the firm might consider consolidating offices in the future, but for now, the companies are highly complementary.

“When you think about the combination of expertise and the massive market need in this space, there's growth opportunities for employees of both organizations,” she said. “Solucient helps round out our offering with a lot of information services for hospital managers as well as pharmaceutical companies.”

Before the acquisition, Thomson Health & Scientific employed 4,700. The firm has been moving away from medical publishing and more heavily into healthcare informatics since its divestiture of its Medical Economics business to Advanstar in October 2003.

Thomson continues to publish PDR. Other Thomson assets include its MercuryMD and Micromedix informatics businesses, aimed at healthcare providers, the CenterWatch suite of products and PDA program Clinical Xpert.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.